What is Longeveron?
Longeveron Inc. is a clinical-stage biotechnology firm focused on developing cellular therapies for aging-related and life-threatening conditions. Headquartered in Miami, Florida, the company's primary investigational product is LOMECEL-B, an allogeneic mesenchymal stem cell formulation derived from young, healthy donors. Longeveron is actively engaged in multiple clinical trial phases (Phase 1, 1/2, 2a, and 2b) across indications such as aging-related frailty and Alzheimer's disease, aiming to address unmet medical needs in regenerative medicine.
How much funding has Longeveron raised?
Longeveron has raised a total of $46.8M across 5 funding rounds:
Debt
$150K
Share Placement
$20M
Private Equity
$6.4M
Unspecified
$4.4M
Private Equity
$15.9M
Debt (2020): $150K with participation from PPP
Share Placement (2021): $20M, investors not publicly disclosed
Private Equity (2024): $6.4M, investors not publicly disclosed
Unspecified (2024): $4.4M, investors not publicly disclosed
Private Equity (2026): $15.9M, investors not publicly disclosed
What's next for Longeveron?
The substantial enterprise-level funding and recent strategic investment indicate Longeveron is poised for significant operational expansion and clinical development acceleration. This capital infusion is expected to fuel the progression of its LOMECEL-B therapy through advanced clinical trials, potentially paving the way for regulatory submissions and commercialization. The company's focus on aging-related diseases positions it within a rapidly growing market, and this financing will be crucial for navigating the complex and capital-intensive path of drug development and market entry.
See full Longeveron company page
